نظرة سريعة
Oxford University begins human trials for the world's first AI-designed vaccine, targeting Crimean-Congo haemorrhagic fever (CCHF), a deadly virus with 40% mortality rates and no widely approved vaccine, using AI to accelerate development by analyzing genetic data to identify immune response triggers.
ملخص مُنشأ بالذكاء الاصطناعي
Oxford University begins human trials for the world's first AI-designed vaccine, targeting Crimean-Congo haemorrhagic fever (CCHF), a deadly virus with 40% mortality rates and no widely approved vaccine, using AI to accelerate development by analyzing genetic data to identify immune response triggers.